
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Case Rep Ophthalmol</journal-id><journal-id journal-id-type="iso-abbrev">Case Rep Ophthalmol</journal-id><journal-id journal-id-type="publisher-id">COP</journal-id><journal-title-group><journal-title>Case Reports in Ophthalmology</journal-title></journal-title-group><issn pub-type="epub">1663-2699</issn><publisher><publisher-name>S. Karger AG</publisher-name><publisher-loc>Allschwilerstrasse 10, P.O. Box &#x000b7; Postfach &#x000b7; Case postale, CH&#x02013;4009, Basel, Switzerland &#x000b7; Schweiz &#x000b7; Suisse, Phone: +41 61 306 11 11, Fax: +41 61 306 12 34, karger@karger.ch</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">22548046</article-id><article-id pub-id-type="pmc">3339664</article-id><article-id pub-id-type="doi">10.1159/000337481</article-id><article-id pub-id-type="publisher-id">cop-0003-0123</article-id><article-categories><subj-group subj-group-type="heading"><subject>Published: March, 2012</subject></subj-group></article-categories><title-group><article-title>Adult Coats&#x02019; Disease Successfully Managed with the Dexamethasone Intravitreal Implant (Ozurdex&#x000ae;) Combined with Retinal Photocoagulation</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Mart&#x000ed;nez-Castillo</surname><given-names>Sebasti&#x000e1;n</given-names></name><xref ref-type="aff" rid="aff1"><sup>a</sup></xref><xref ref-type="corresp" rid="cor1">*</xref></contrib><contrib contrib-type="author"><name><surname>Gallego-Pinazo</surname><given-names>Roberto</given-names></name><xref ref-type="aff" rid="aff1"><sup>a</sup></xref></contrib><contrib contrib-type="author"><name><surname>Dolz-Marco</surname><given-names>Rosa</given-names></name><xref ref-type="aff" rid="aff1"><sup>a</sup></xref></contrib><contrib contrib-type="author"><name><surname>Mar&#x000ed;n-Lamb&#x000ed;es</surname><given-names>Cristina</given-names></name><xref ref-type="aff" rid="aff1"><sup>a</sup></xref></contrib><contrib contrib-type="author"><name><surname>D&#x000ed;az-Llopis</surname><given-names>Manuel</given-names></name><xref ref-type="aff" rid="aff1"><sup>a</sup></xref><xref ref-type="aff" rid="aff2"><sup>b</sup></xref></contrib></contrib-group><aff id="aff1"><sup>a</sup>Department of Ophthalmology, University and Polytechnic Hospital La Fe, Valencia, Spain</aff><aff id="aff2"><sup>b</sup>Faculty of Medicine, University of Valencia, Valencia, Spain</aff><author-notes><corresp id="cor1">*Sebasti&#x000e1;n Mart&#x000ed;nez-Castillo, University and Poly technic Hospital La Fe, B ulevar Sur, s/n, ES-46026 Valencia (Spain), Tel. +34 639 543 109, E-Mail <email>s.martinez@comv.es</email></corresp></author-notes><pub-date pub-type="collection"><season>Jan-Apr</season><year>2012</year></pub-date><pub-date pub-type="epub"><day>26</day><month>3</month><year>2012</year></pub-date><pub-date pub-type="pmc-release"><day>26</day><month>3</month><year>2012</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on the
							<pub-date pub-type="epub"/>. --><volume>3</volume><issue>1</issue><fpage>123</fpage><lpage>127</lpage><permissions><copyright-statement>Copyright &#x000a9; 2012 by S. Karger AG, Basel</copyright-statement><copyright-year>2012</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-nd/3.0/"><license-p><!--CREATIVE COMMONS-->This is an Open Access article distributed under the terms of the Creative Commons Attribution-Noncommercial-No-Derivative-Works License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/3.0/">http://creativecommons.org/licenses/by-nc-nd/3.0/</ext-link>). Users may download, print and share this work on the Internet for noncommercial purposes only, provided the original work is properly cited, and a link to the original work on <ext-link ext-link-type="uri" xlink:href="http://www.karger.com">http://www.karger.com</ext-link> and the terms of this license are included in any shared versions.</license-p></license></permissions><abstract><sec><title>Purpose</title><p>To report a case of Coats&#x02019; disease managed with the dexamethasone intravitreal implant Ozurdex<sup>&#x000ae;</sup> (Allergan, Inc., Irvine, Calif., USA) combined with retinal photocoagulation.</p></sec><sec><title>Methods</title><p>A 46-year-old female with 20/200 visual acuity was diagnosed with Coats&#x02019; disease with secondary retinal vasoproliferative tumor. An initial approach was performed with an intravitreal injection of the sustained-release dexamethasone implant Ozurdex. After reattachment of the retina, the telangiectatic vessels were treated with laser photocoagulation.</p></sec><sec><title>Results</title><p>The patient's visual acuity improved to 20/25 after the intravitreal Ozurdex. No further recurrences of exudation were evident through the 12-month follow-up.</p></sec><sec><title>Conclusions</title><p>Ozurdex may be an effective initial therapeutic approach for Coats&#x02019; disease with immediate anatomical response and visual improvement.</p></sec></abstract><kwd-group><title>Key words</title><kwd>Coats&#x02019; disease</kwd><kwd>Retinal telangiectasis</kwd><kwd>Retinal vasoproliferative tumor</kwd><kwd>Dexamethasone intravitreal implant (Ozurdex<sup>&#x000ae;</sup>)</kwd></kwd-group><counts><fig-count count="3"/><ref-count count="14"/><page-count count="5"/></counts></article-meta></front><body><sec id="sec1_1"><title>Introduction</title><p>Coats&#x02019; disease is a unilateral, idiopathic retinal vascular abnormality characterized by telangiectatic retinal vessels in association with lipid exudation [<xref ref-type="bibr" rid="B1">1</xref>]. Although most cases are diagnosed before the age of 20 years, Coats&#x02019; disease may also be diagnosed in adult patients [<xref ref-type="bibr" rid="B2">2</xref>]. Current therapeutic strategies include observation, ablation of abnormal retinal telangiectasis by photocoagulation &#x02013; or cryotherapy &#x02013; and surgery for retinal detachment. Recent publications regarding the off-label use of triamcinolone [<xref ref-type="bibr" rid="B3">3</xref>, <xref ref-type="bibr" rid="B4">4</xref>] or vascular endothelial growth factor inhibitors [<xref ref-type="bibr" rid="B5">5</xref>, <xref ref-type="bibr" rid="B6">6</xref>, <xref ref-type="bibr" rid="B7">7</xref>] have been published with inconclusive outcomes, requiring several rounds of retreatment in most cases. The purpose of any treatment for Coats&#x02019; disease is to establish a prompt and long-standing visual recovery, with the safest profile for patients.</p></sec><sec id="sec1_2"><title>Case Report</title><p>A 46-year-old female was referred to our department with a 3-week history of progressive vision loss in her left eye. The best corrected visual acuity (BCVA) was 20/20 in her right eye and 20/200 in her left eye. Anterior segment examination was unremarkable.</p><p>Whereas the right eye fundus did not show any significant change, in the left eye massive exudation within the inferior-temporal quadrant of the retina was evident, with posterior pole involvement and intraretinal lipid accumulation. In addition, a grayish mass was observed in the inferior peripheral retina (<bold>fig. <xref ref-type="fig" rid="F1">1</xref></bold>). Spectral-domain optical coherence tomography (SD-OCT) confirmed the presence of exudative retinal detachment with macular involvement (fig. <xref ref-type="fig" rid="F1">1</xref>). Numerous hyperreflective intraretinal lesions corresponding to lipids were evident. An echography showed an intraretinal mass (4.1 &#x000d7; 1.9 mm) located in the inferior periphery, associated with the exudative retinal detachment (fig. <xref ref-type="fig" rid="F1">1</xref>). Fluorescein angiography (fig. <xref ref-type="fig" rid="F1">1</xref>) revealed the presence of telangiectatic vessels scattered all over the inferior-temporal retinal quadrant; the peripheral inferior mass was identified as a retinal vasoproliferative tumor (RVT) with clearly defined afferent and efferent vessels.</p><p>With the presumptive diagnosis of Coats&#x02019; disease with exudative inferior-temporal retinal detachment and secondary RVT, the patient was treated with an intravitreal injection of the sustained-release dexamethasone implant Ozurdex<sup>&#x000ae;</sup> (Allergan, Inc., Irvine, Calif., USA). One week later, her BCVA improved to 20/40 and SD-OCT revealed a complete resolution of the exudative retinal detachment (<bold>fig. <xref ref-type="fig" rid="F2">2</xref></bold>). The telangiectatic vessels were treated with laser photocoagulation guided by fluorescein angiography in 3 consecutive sessions with 15-day intervals. The volume of the RVT decreased progressively until complete retinographic and echographic disappearance.</p><p>Through the follow-up, no further recurrences of the exudative retinal detachment were found, and the extensive lipid exudation progressively regressed. One year after initial treatment with intravitreal Ozurdex, the patient's BCVA was 20/25 (<bold>fig. <xref ref-type="fig" rid="F3">3</xref></bold>).</p></sec><sec sec-type="discussion" id="sec1_3"><title>Discussion</title><p>The pathogenesis of Coats&#x02019; disease includes impairment of the blood-retinal barrier resulting in both intraretinal and subretinal fluid, and blood and lipid accumulation. In addition, weakening of the retinal vessel walls leads to the formation of telangiectasis, aneurysms and progressive leakage, resulting in exudative retinal detachment [<xref ref-type="bibr" rid="B8">8</xref>]. One of the possible complications of Coats&#x02019; disease is the development of secondary RVT [<xref ref-type="bibr" rid="B9">9</xref>], as evidenced in our patient's case.</p><p>Intravitreal injection of dexamethasone has been shown to attenuate leukostasis and vascular leakage [<xref ref-type="bibr" rid="B10">10</xref>]. This fact may be of great help in the management of Coats&#x02019; disease, given the underlying inflammatory component [<xref ref-type="bibr" rid="B11">11</xref>]. Ozurdex is a novel, biodegradable, sustained-release dexamethasone delivery system approved for the treatment of macular edema following retinal vein occlusion [<xref ref-type="bibr" rid="B12">12</xref>]. Recently published clinical trials expand the efficacy of Ozurdex to the management of diabetic macular edema [<xref ref-type="bibr" rid="B13">13</xref>] and uveitic macular edema [<xref ref-type="bibr" rid="B14">14</xref>].</p><p>In our patient's case, a single injection of Ozurdex was able to dramatically improve visual acuity and resolve the exudative retinal detachment. Further photocoagulation may lead to closure of telangiectasis; no further recurrence of exudation was seen through a 12-month follow-up. Further studies are warranted in order to confirm the high efficacy of Ozurdex in the initial management of Coats&#x02019; disease.</p></sec></body><back><ref-list><title>References</title><ref id="B1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coats</surname><given-names>G</given-names></name></person-group><article-title>Forms of retinal diseases with massive exudation</article-title><source>Roy Lond Ophthalmol Hosp Rep</source><year>1908</year><volume>17</volume><fpage>440</fpage><lpage>525</lpage></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smithen</surname><given-names>LM</given-names></name><name><surname>Brown</surname><given-names>GC</given-names></name><name><surname>Brucker</surname><given-names>AJ</given-names></name><name><surname>Yannuzzi</surname><given-names>LA</given-names></name><name><surname>Klais</surname><given-names>CM</given-names></name><name><surname>Spaide</surname><given-names>RF</given-names></name></person-group><article-title>Coats' disease diagnosed in adulthood</article-title><source>Ophthalmology</source><year>2005</year><volume>112</volume><fpage>1072</fpage><lpage>1078</lpage><pub-id pub-id-type="pmid">15882905</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bergstrom</surname><given-names>CS</given-names></name><name><surname>Hubbard</surname><given-names>GB</given-names><suffix>3rd</suffix></name></person-group><article-title>Combination intravitreal triamcinolone injection and cryotherapy for exudative retinal detachments in severe Coats disease</article-title><source>Retina</source><year>2008</year><volume>28</volume><issue>3 suppl</issue><fpage>S33</fpage><lpage>S37</lpage><pub-id pub-id-type="pmid">18317342</pub-id></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Othman</surname><given-names>IS</given-names></name><name><surname>Moussa</surname><given-names>M</given-names></name><name><surname>Bouhaimed</surname><given-names>M</given-names></name></person-group><article-title>Management of lipid exudates in Coats disease by adjuvant intravitreal triamcinolone: effects and complications</article-title><source>Br J Ophthalmol</source><year>2010</year><volume>94</volume><fpage>606</fpage><lpage>610</lpage><pub-id pub-id-type="pmid">19955197</pub-id></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Venkatesh</surname><given-names>P</given-names></name><name><surname>Mandal</surname><given-names>S</given-names></name><name><surname>Garg</surname><given-names>S</given-names></name></person-group><article-title>Management of Coats disease with bevacizumab in 2 patients</article-title><source>Can J Ophthalmol</source><year>2008</year><volume>43</volume><fpage>245</fpage><lpage>246</lpage><pub-id pub-id-type="pmid">18347637</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goel</surname><given-names>N</given-names></name><name><surname>Kumar</surname><given-names>V</given-names></name><name><surname>Seth</surname><given-names>A</given-names></name><name><surname>Raina</surname><given-names>UK</given-names></name><name><surname>Ghosh</surname><given-names>B</given-names></name></person-group><article-title>Role of intravitreal bevacizumab in adult onset Coats' disease</article-title><source>Int Ophthalmol</source><year>2011</year><volume>31</volume><fpage>183</fpage><lpage>190</lpage><pub-id pub-id-type="pmid">21437759</pub-id></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Diago</surname><given-names>T</given-names></name><name><surname>Valls</surname><given-names>B</given-names></name><name><surname>Pulido</surname><given-names>JS</given-names></name></person-group><article-title>Coats' disease associated with muscular dystrophy treated with ranibizumab</article-title><source>Eye (Lond)</source><year>2010</year><volume>24</volume><fpage>1295</fpage><lpage>1296</lpage><pub-id pub-id-type="pmid">20075964</pub-id></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Woods</surname><given-names>AC</given-names></name><name><surname>Duke</surname><given-names>JR</given-names></name></person-group><article-title>Coats' disease. I. Review of literature, diagnostic criteria, clinical findings and plasma lipid studies</article-title><source>Br J Ophthalmol</source><year>1963</year><volume>47</volume><fpage>385</fpage><lpage>412</lpage><pub-id pub-id-type="pmid">14189710</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shields</surname><given-names>JA</given-names></name><name><surname>Shields</surname><given-names>CL</given-names></name><name><surname>Honavar</surname><given-names>SG</given-names></name><name><surname>Demirci</surname><given-names>H</given-names></name></person-group><article-title>Clinical variations and complications of Coats disease in 150 cases. The 2000 Sanford Gifford Memorial Lecture</article-title><source>Am J Ophthalmol</source><year>2001</year><volume>131</volume><fpage>561</fpage><lpage>571</lpage><pub-id pub-id-type="pmid">11336930</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tamura</surname><given-names>H</given-names></name><name><surname>Miyamoto</surname><given-names>K</given-names></name><name><surname>Kiryu</surname><given-names>J</given-names></name><name><surname>Miyahara</surname><given-names>S</given-names></name><name><surname>Katsuta</surname><given-names>H</given-names></name><name><surname>Hirose</surname><given-names>F</given-names></name><name><surname>Musashi</surname><given-names>K</given-names></name><name><surname>Yoshimura</surname><given-names>N</given-names></name></person-group><article-title>Intravitreal injection of corticosteroid attenuates leukostasis and vascular leakage in experimental diabetic retina</article-title><source>Invest Ophthalmol Vis Sci</source><year>2005</year><volume>46</volume><fpage>1440</fpage><lpage>1444</lpage><pub-id pub-id-type="pmid">15790913</pub-id></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lim</surname><given-names>WK</given-names></name><name><surname>Nussenblatt</surname><given-names>RB</given-names></name><name><surname>Chan</surname><given-names>CC</given-names></name></person-group><article-title>Immunopathologic features of inflammatory coats disease</article-title><source>Arch Ophthalmol</source><year>2005</year><volume>123</volume><fpage>279</fpage><lpage>281</lpage><pub-id pub-id-type="pmid">15710836</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haller</surname><given-names>JA</given-names></name><name><surname>Bandello</surname><given-names>F</given-names></name><name><surname>Belfort</surname><given-names>R</given-names><suffix>Jr</suffix></name><name><surname>Blumenkranz</surname><given-names>MS</given-names></name><name><surname>Gillies</surname><given-names>M</given-names></name><name><surname>Heier</surname><given-names>J</given-names></name><name><surname>Loewenstein</surname><given-names>A</given-names></name><name><surname>Yoon</surname><given-names>YH</given-names></name><name><surname>Jacques</surname><given-names>ML</given-names></name><name><surname>Jiao</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>XY</given-names></name><name><surname>Whitcup</surname><given-names>SM</given-names></name><collab>OZURDEX GENEVA Study Group</collab></person-group><article-title>Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion</article-title><source>Ophthalmology</source><year>2010</year><volume>117</volume><fpage>1134</fpage><lpage>1146.e3</lpage><pub-id pub-id-type="pmid">20417567</pub-id></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boyer</surname><given-names>DS</given-names></name><name><surname>Faber</surname><given-names>D</given-names></name><name><surname>Gupta</surname><given-names>S</given-names></name><name><surname>Patel</surname><given-names>SS</given-names></name><name><surname>Tabandeh</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>XY</given-names></name><name><surname>Liu</surname><given-names>CC</given-names></name><name><surname>Lou</surname><given-names>J</given-names></name><name><surname>Whitcup</surname><given-names>SM</given-names></name><collab>for the Ozurdex CHAMPLAIN Study Group</collab></person-group><article-title>Dexamethasone intravitreal implant for treatment of diabetic macular edema in vitrectomized patients</article-title><source>Retina</source><year>2011</year><volume>31</volume><fpage>915</fpage><lpage>923</lpage><pub-id pub-id-type="pmid">21487341</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lowder</surname><given-names>C</given-names></name><name><surname>Belfort</surname><given-names>R</given-names><suffix>Jr</suffix></name><name><surname>Lightman</surname><given-names>S</given-names></name><name><surname>Foster</surname><given-names>CS</given-names></name><name><surname>Robinson</surname><given-names>MR</given-names></name><name><surname>Schiffman</surname><given-names>RM</given-names></name><name><surname>Li</surname><given-names>XY</given-names></name><name><surname>Cui</surname><given-names>H</given-names></name><name><surname>Whitcup</surname><given-names>SM</given-names></name><collab>Ozurdex HURON Study Group</collab></person-group><article-title>Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis</article-title><source>Arch Ophthalmol</source><year>2011</year><volume>129</volume><fpage>545</fpage><lpage>553</lpage><pub-id pub-id-type="pmid">21220619</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="F1" orientation="portrait" position="float"><label>Fig. 1</label><caption><p><bold>a</bold> Retinography of the left eye reveals massive exudation within the inferior-temporal quadrant of the retina. <bold>b</bold> Horizontal and vertical (<bold>c</bold>) OCT scans (indicated as B and C, respectively, in <bold>a</bold>) centered in the fovea confirm the presence of exudative retinal detachment with macular involvement. <bold>d</bold> Fluorescein angiography shows the presence of telangiectatic vessels scattered all over the inferior-temporal retinal quadrant.</p></caption><graphic xlink:href="cop-0003-0123-g01"/></fig><fig id="F2" orientation="portrait" position="float"><label>Fig. 2</label><caption><p><bold>a</bold> Retinography shows the presence of the Ozurdex<sup>&#x000ae;</sup> device 1 week after its implantation. <bold>b</bold> Horizontal OCT scan and 3-dimensional reconstruction (<bold>c</bold>) show the presence of the implant adjacent to the retinal vasoproliferative tumor.</p></caption><graphic xlink:href="cop-0003-0123-g02"/></fig><fig id="F3" orientation="portrait" position="float"><label>Fig. 3</label><caption><p>Retinography after 12 months of follow-up reveals regression of lipid exudation and retinal scars from photocoagulation.</p></caption><graphic xlink:href="cop-0003-0123-g03"/></fig></floats-group></article>